GlassScriptPhysician profile
Ashley Anderson Mccormack
NPI 1003455361
$7,159.60
in general payments reported to CMS, 2019-2025
24 companies · $1,254 in 2025
The $1,254 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,207 · 2022: $847 · 2023: $1,777 · 2024: $2,075 · 2025: $1,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,469 · Education: $636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,469.46 |
| Education | $635.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,365.75 | 2021-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $1,092.71 | 2022-2025 | Sotyktu |
| Abbvie INC. | $754.88 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $709.67 | 2021-2025 | Dupixent |
| Genzyme Corporation | $636.03 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $620.57 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Novartis Pharmaceuticals Corporation | $607.77 | 2022-2025 | |
| Pfizer INC. | $308.38 | 2021-2025 | |
| Ucb, INC. | $205.82 | 2021-2025 | Bimzelx |
| Amgen INC. | $181.17 | 2022-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $177.72 | 2023-2025 | Oracea, Aklief, Epsolay |
| Lilly USA, LLC | $117.44 | 2022-2024 | Olumiant, Ebglyss, Taltz |
| Sanofi-Aventis U.S. LLC | $85.00 | 2025 | |
| Verrica Pharmaceuticals INC. | $35.81 | 2024 | Ycanth |
| Mayne Pharma Commercial LLC | $35.73 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $32.96 | 2023-2024 | Adbry |
| Dermavant Sciences, INC. | $30.20 | 2023-2024 | Vtama |
| Kyowa Kirin, INC. | $25.54 | 2024 | Poteligeo |
| Teva Pharmaceuticals USA, INC. | $24.81 | 2024 | |
| Incyte Corporation | $23.85 | 2023 | Opzelura |
| Lnhc, INC | $23.29 | 2025 | Zelsuvmi |
| Botanix Sb INC | $23.13 | 2025 | Sofdra |
| Fresenius Kabi USA, LLC | $22.60 | 2024 | |
| Arcutis Biotherapeutics, INC. | $18.77 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Mccormack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.